DOCSLIB.ORG

Efficacy of Levodropropizine in the Pediatric Setting: a Meta-Analysis of Published Studies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Efficacy of Levodropropizine in the Pediatric Setting: a Meta-Analysis of Published Studies Review Efficacy of levodropropizine in the pediatric setting: a meta-analysis of published studies Summary Cough in children is among the most common symptoms and may have a deep impact on children’s and parents’ sleep and quality of life, thus often requiring an empiric treatment with antitussive agents. Levodro- propizine is a very well tolerated peripheral drug, while central cough suppressants (opioids and non opioids) may be associated with side effects that limit their use especially in children. After comprehensive literature search, a meta-analysis of 4 clinical studies of levodropropizine vs. control, including a total of 780 patients, was performed with the aim to evaluate the overall comparative efficacy of levodropropizine in the pediatric population. Meta-analysis of all standardized efficacy parameters (cough frequency, severity, and night awake- nings) showed a highly statistically significant difference in the overall antitussive efficacy in favor of levodro- propizine vs. control treatments (p=0.0044). The heterogeneity test for the efficacy outcome was not statisti- cally significant (p=0.0856). Our meta-analysis indicates that levodropropizine is an effective antitussive drug in children, with statistically significant better overall efficacy outcomes vs. central antitussives (codeine, clope- rastine, dextromethorphan), in terms of reducing cough intensity, frequency and nocturnal awakenings. These results further reinforce the favorable benefit/risk profile of levodropropizine in the management of cough in the pediatric setting. De Blasio F, Lanata L, Dicpingaitis PV, et al. Efficacy of levodropropizine in the pediatric setting: a meta-analysis of published studies. Trends Med 2013; 13(1):9-14. ©2013 Pharma Project Group srl. ISSN: 1594-2848 1 Francesco De Blasio , Luigi Introduction Cough resulting from URTI, al- Lanata2, Peter V. Dicpingaitis3, Federico Saibene2, Rossella Cough in children is among the though usually self-limiting Balsamo2, Alessandro Zanasi4 most common problems refer- within 7 to 15 days, may be a 1Respiratory Medicine and Pulmonary red to pediatricians, and occurs distressing symptom that causes Rehabilitation Section, Clinic Center, significant anxiety to parents for Private Hospital, Naples, Italy more frequently in preschool 2Medical Department, Dompé SPA, than in older children1,2. its frequency and severity. Cou- Milan, Italy The etiology and management gh may have a deep impact on 3Department of Medicine, Albert Einstein the sleep of both children and College of Medicine and Montefiore approach for cough in children Medical Center, Bronx, NY, USA differs greatly to that in adults, parents, on the children’s scho- 4Pneumology Unit, University of so the empirical approach com- lastic and sport activities and Bologna, S.Orsola Malpighi Hospital, thus on their quality of life4,5. Bologna, Italy monly used in adults is unsuita- ble for children3. Clinical evalua- Therefore, an empiric treatment tion of cough in children should with antitussive agents is often include an assessment of envi- used in pediatric cough, even Key words: ronmental factors, particularly though the administration of levodropropizine tobacco smoke, parental concer- inappropriate or unnecessary pediatric ns and expectations4. medications for cough may be antitussives 1,6 Most children with acute cough associated with side effects . cough Mainly two classes of antitussi- meta-analysis are likely to have an uncompli- cated viral acute upper respira- ve drugs are available for the tre- atment of cough in children: Federico Saibene tory tract infection (URTI), but the possibility of a more serious centrally acting (opioids and non Medical Department, opioids) cough suppressants, Dompé SPA, problem, especially aspiration Milan, Italy of foreign material, should and peripherally acting antitus- e-mail: [email protected] always be considered2,4. sives. Codeine, dextromethor- January 2013 Volume 13 Number 1 Trends in Medicine 9 F. De Blasio, L. Lanata, P.V. Dicpingaitis, et al. phan and cloperastine are A meta-analysis of studies me- zine were performed vs. central among the most common cen- eting eligibility criteria was per- antitussives (Banderali 199513, trally acting agents that are be- formed with the aim to evalua- Kim 200214, and De Blasio lieved to inhibit cough primari- te the overall efficacy of levo- 20127), while one study was per- ly by their effect on the cough dropropizine versus control in formed vs. placebo (Fiocchi center, while levodropropizine is children. Due to the small num- 199115). an orally administered non- ber of clinical trials in the pe- The study of De Blasio et al.7 opioid agent exerting periphe- diatric population and conside- evaluated the use of antitussive ral antitussive action that resul- ring their different clinical en- drugs in 433 children who re- ts from inhibition of the cough dpoints, the efficacy variables of quired medical consultation for reflex at the peripheral nerve the selected studies were stan- acute cough. A subgroup of 161 level (sensory C fibres) with dardized in order to allow com- children received antitussive tre- modulation of sensory neuro- parison of the overall efficacy atment with levodropropizine peptides within the respiratory of levodropropizine versus con- (N = 101) or central cough sup- tract7-9. trol groups. Our meta-analysis pressants (codeine or cloperasti- In recent years, much attention was performed after standardi- ne, N = 60). Both peripheral and has been drawn to the fact that zation on the overall efficacy central antitussives were effec- some antitussive agents com- variables assessed as endpoints tive in reducing the frequency monly used in the pediatric po- in the eligible studies (i.e., reduc- and intensity of cough. Howe- pulation are not supported by tion in cough frequency, cough ver, a significant advantage was adequate efficacy data, especially severity, and night awakenings). observed for levodropropizine in light of potentially associated For each study, original Abso- vs. central drugs in terms of hi- side effects1. Centrally acting lute Mean Delta were calculated gher cough resolution (p = cough suppressants, although as the mean differences betwe- 0.0012) and lower unsuccessful largely used, have no consistent en the baseline and final values treatment. The superiority of evidence of efficacy and there of efficacy parameters in levo- the peripheral antitussive levo- are increasing reports of asso- dropropizine and control dropropizine vs. central drugs in ciation with serious adverse groups, with the respective (ap- terms of cough resolution was events in children3. proximate) standard deviations independent from cough seve- (SD) and the number of cases rity, with statistically significant Methods (N) studied in single treatment difference also in the subgroups groups. Standardized Mean Del- of patients with higher cough A comprehensive systematic li- ta were calculated by means of intensity (moderate and severe). terature search was performed the original Absolute Mean Del- In a double blind randomized on the main electronic databa- ta (with their SD and N) and study carried out by Kim et al.14, ses (PubMed/MEDLINE, represent a fraction or multiple the efficacy of levodropropizi- EMBASE, and Cochrane Li- of unitary standard deviations, ne was compared to the central brary) from their inception expressed as standardized uni- antitussive dextromethorphan throughout January 2012, to ts10-12. in 77 children with bronchitis. identify original clinical studies After 2-3 days of administra- of levodropropizine for the tre- Study Selection tion, both severity and frequen- atment of cough in the pedia- cy of cough were reduced more tric population. A total of 9 published clinical significantly in the levodropro- The inclusion criteria used to studies conducted with levodro- pizine group than in the dextro- select studies were established a propizine in the pediatric setting methorphan group (p = 0.003). priori. Only controlled studies were identified by means of our Also the final efficacy score re- (vs. both active control and pla- systematic literature search, in- sulted significantly higher with cebo) including pediatric patien- volving an overall population of levodropropizine vs. dextro- ts and assessing efficacy en- 1242 children. methorphan (p = 0.003), dpoints related to cough outco- Out of these, 4 studies including showing a more favorable anti- mes were selected for our analy- a total of 780 patients met the tussive effectiveness of levodro- sis. Non controlled studies and eligibility criteria and were se- propizine in comparison to dex- studies evaluating only safety lected for our meta-analysis. tromethorphan. endpoints were excluded. Three studies of levodropropi- Banderali et al.13 evaluated in a 10 Trends in Medicine January 2013 Volume 13 Number 1 Efficacy of levodropropizine in the pediatric setting double blind randomized study antitussive efficacy of levodro- nings) assessed in each of the the efficacy of levodropropizi- propizine vs. control in the pe- eligible clinical studies, both in ne compared to dropropizine in diatric setting are summarized in levodropropizine and control the management of non-pro- Table 1. groups. ductive cough in 258 pediatric Main efficacy outcomes of the The results of the standardiza- patients. The results demonstra- 4 clinical trials included in this tion of different efficacy varia- ted statistically significant decre- meta-analysis were frequency of bles, in order to
Load more

Recommended publications
  • Update on Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
    J Bras Pneumol. 2015;41(5):454-466 http://dx.doi.org/10.1590/S1806-37132015000000152 REVIEW ARTICLE Update on diagnosis and treatment of idiopathic pulmonary fibrosis José Baddini-Martinez1, Bruno Guedes Baldi2, Cláudia Henrique da Costa3, Sérgio Jezler4, Mariana Silva Lima5, Rogério Rufino3,6 1. Divisão de Pneumologia, Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Brasil. 2. Divisão de Pneumologia, Instituto do Coração, Hospital das Clínicas, ABSTRACT Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brasil. Idiopathic pulmonary fibrosis is a type of chronic fibrosing interstitial pneumonia, of 3. Disciplina de Pneumologia e Tisiologia, unknown etiology, which is associated with a progressive decrease in pulmonary Faculdade de Ciências Médicas, function and with high mortality rates. Interest in and knowledge of this disorder have Universidade do Estado do Rio de grown substantially in recent years. In this review article, we broadly discuss distinct Janeiro, Rio de Janeiro, Brasil. aspects related to the diagnosis and treatment of idiopathic pulmonary fibrosis. We 4. Ambulatório de Pneumologia, Hospital list the current diagnostic criteria and describe the therapeutic approaches currently Ana Nery, Salvador, Brasil. available, symptomatic treatments, the action of new drugs that are effective in slowing 5. Ambulatório de Doenças Pulmonares Intersticiais, Hospital do Servidor the decline in pulmonary function, and indications for lung transplantation. Público Estadual de São Paulo, São Keywords: Idiopathic pulmonary fibrosis/diagnosis; Idiopathic pulmonary fibrosis/therapy; Paulo, Brasil. Idiopathic pulmonary fibrosis/rehabilitation. 6. Programa de Pós-Graduação em Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.
    [Show full text]
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • Efficacy of Different Types of Therapy for COVID-19
    life Review Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review Anna Starshinova 1,*, Anna Malkova 2 , Ulia Zinchenko 3 , Dmitry Kudlay 4,5 , Anzhela Glushkova 6, Irina Dovgalyk 3, Piotr Yablonskiy 2,3 and Yehuda Shoenfeld 2,7,8 1 Almazov National Medical Research Centre, Head of the Research Department, 2 Akkuratov Str., 197341 Saint-Petersburg, Russia 2 Medical Department, Saint Petersburg State University, 199034 Saint-Petersburg, Russia; [email protected] (A.M.); [email protected] (P.Y.); [email protected] (Y.S.) 3 St. Petersburg Research Institute of Phthisiopulmonology, 199034 Saint-Petersburg, Russia; [email protected] (U.Z.); [email protected] (I.D.) 4 NRC Institute of Immunology FMBA of Russia, 115478 Moscow, Russia; [email protected] 5 Medical Department, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia 6 V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, 192019 Saint Petersburg, Russia; [email protected] 7 Ariel University, Kiryat HaMada 3, Ariel 40700, Israel 8 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 5265601, Israel * Correspondence: [email protected]; Tel.: +7-9052043861 Citation: Starshinova, A.; Malkova, Abstract: A new coronavirus disease (COVID-19) has already affected millions of people in 213 coun- A.; Zinchenko, U.; Kudlay, D.; tries. The possibilities of treatment have been reviewed in recent publications but there are many Glushkova, A.; Dovgalyk, I.; controversial results and conclusions. An analysis of the studies did not reveal a difference in Yablonskiy, P.; Shoenfeld, Y. Efficacy mortality level between people treated with standard therapy, such as antiviral drugs and dexam- of Different Types of Therapy for ethasone, and new antiviral drugs/additional immune therapy.
    [Show full text]
  • Development and Validation of a Stability-Indicating LC-Method For
    Sci Pharm www.scipharm.at Research article Open Access Development and Validation of a Stability-Indicating LC-Method for the Simultaneous Estimation of Levodropropizine, Chloropheniramine, Methylparaben, Propylparaben, and Levodropropizine Impurities 1 1 Palakurthi Ashok KUMAR * , Thummala Veera Raghava RAJU , 1 1 2 Dongala THIRUPATHI , Ravindra KUMAR , Jaya SHREE 1 Analytical Research and Development, Integrated Product Development, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad-500 072, India. 2 Centre for Chemical Science and Technology, J. N. T. University, Kukatpally, Hyderabad, A.P., India. * Corresponding author. E-mail: [email protected] (P. A. Kumar) Sci Pharm. 2013; 81: 139–150 doi:10.3797/scipharm.1210-18 Published: November 17th 2012 Received: October 18th 2012 Accepted: November 17th 2012 This article is available from: http://dx.doi.org/10.3797/scipharm.1210-18 © Kumar et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract A simple, fast, and efficient RP-HPLC method has been developed and validated for the simultaneous estimation of Levodropropizine, Chloropheniramine, Methylparaben, Propylparaben, and the quantification of Levodropropizine impurities in the Reswas syrup dosage form. A gradient elution method was used for the separation of all the actives and Levodropropizine impurities by using the X-Bridge C18, 150 mm × 4.6 mm, 3.5 μm column with a flow rate of 1.0 mL/min and detector wavelength at 223 nm.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • Poison Act 1952
    LAWS OF MALAYSIA _____________ ONLINE VERSION OF UPDATED TEXT OF REPRINT _____________ Act 366 POISONS ACT 1952 As at 1 February 2019 2 POISONS ACT 1952 First enacted … … … … 1952 (Ord. No. 29 of 1952) Revised … … … … 1989 (Act 366 w.e.f. 13 April 1989) Latest amendment made by P.U. (A) 8/2019 which came into operation on … … 10 January 2019 PREVIOUS REPRINTS First Reprint ... ... ... ... ... 2001 Second Reprint ... ... ... ... ... 2006 3 LAWS OF MALAYSIA Act 366 POISONS ACT 1952 ARRANGEMENT OF SECTIONS Section 1. Short title and application 2. Interpretation 3. Establishment of Poisons Board 4. Proceedings of Board 5. Powers of Board to regulate proceedings 6. Power of Minister to amend Poisons List 7. Application of the Act 8. Control of imports of poisons 9. Packaging, labelling and storing of poisons 10. Transport of poisons 11. Control of manufacture of preparations containing poison 12. Control of compounding of poisons for use in medical treatment 13. Possession for sale of poison and sale of poison in contravention of this Act an offence 14. Control of acetylating substances 15. Sale of poisons by wholesale 16. Sale of poisons by retail 17. Prohibition of sale to persons under 18 18. Restriction on the sale of Part I poisons generally 19. Supply of poisons for the purpose of treatment by professional men 20. Group A Poisons 21. Group B Poisons 4 Laws of Malaysia ACT 366 Section 22. Group C Poisons 23. Group D Poisons 24. Prescription book 25. Sale of Part II Poisons 26. Licences 27. Register of licences 28. Annual list to be published 29.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • A Case of Immunoglobulin E Mediated Anaphylaxis to Levodropropizine
    http://dx.doi.org/10.3349/ymj.2013.54.1.262 Case Report pISSN: 0513-5796, eISSN: 1976-2437 Yonsei Med J 54(1):262-264, 2013 A Case of Immunoglobulin E Mediated Anaphylaxis to Levodropropizine Kyung Hee Park,1,2 Il Seon Yun,1,2 Soo-Young Choi,2 Jae-Hyun Lee,1,2 Chein-Soo Hong,1,2 and Jung-Won Park1,2 1Division of Allergy and Immunology, Department of Internal Medicine, 2Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea. Received: May 17, 2012 We experienced a case of immunoglobulin E (IgE) mediated anaphylaxis to levo- Revised: June 7, 2012 dropropizine. The patient was an 18-year old Korean woman. After taking the Accepted: June 7, 2012 common cold medication including acetaminophen, domperidone, and levodro- Corresponding author: Dr. Jung-Won Park, propizine, skin rash, angioedema and anaphylaxis were developed immediately. Division of Allergy and Immunology, As she was tolerable to acetaminophen alone, we thought the culprit agent was Department of Internal Medicine, Yonsei University College of Medicine, maybe a levodropropizine tablet. To confirm the culprit, she underwent skin prick 50 Yonsei-ro, Seodaemun-gu, test and oral drug provocation test with the suspected one. Finally we detected le- Seoul 120-752, Korea. vodropropizine specific IgE and confirmed the specificity by inhibition enzyme- Tel: 82-2-2228-1961, Fax: 82-2-393-6884 linked immunosorbent assay (ELISA). E-mail: [email protected] Key Words: Levodropropizine, anaphylaxis, drug hypersensitivity ∙ The authors have no financial conflicts of interest. INTRODUCTION Levodropropizine is widely used peripheral acting antitussives. It suppresses cough through inhibition of vagal C-fiber and its neuropeptide.1 Previously report- ed adverse drug reactions of levodropropizine were nausea, diarrhea and epigastric discomfort.2 Only two cases of anaphylaxis to levodropropizine were reported,3,4 but the mechanism of levodropropizine anaphylaxis is not yet clarified.
    [Show full text]
  • WHO-EMP-RHT-TSN-2018.1-Eng.Pdf
    WHO/EMP/RHT/TSN/2018.1 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization [2018] Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO.
    [Show full text]
  • Pharmacological Drugs Inducing Ototoxicity, Vestibular Symptoms and Tinnitus: a Reasoned and Updated Guide
    European Review for Medical and Pharmacological Sciences 2011; 15: 601-636 Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide G. CIANFRONE1, D. PENTANGELO1, F. CIANFRONE2, F. MAZZEI1, R. TURCHETTA1, M.P. ORLANDO1, G. ALTISSIMI1 1Department of Otolaryngology, Audiology and Phoniatrics, “Umberto I” University Hospital, Sapienza University, Rome (Italy); 2Institute of Otorhinolaryngology, School of Medicine, Catholic University of the Sacred Heart, Rome (Italy) Abstract. – The present work on drug-in- Introduction duced ototoxicity, tinnitus and vertigo repre- sents the update and revision of a previous The panorama of the pharmacological origin guide to adverse drug reactions for italian physi- iatrogenic noxae able to induce either harmful cians (2005). The panorama of drug-induced side effects causing ototoxicity or symptoms ototoxic effects or just a symptomatology like tin- such as tinnitus or dizziness and vertigo has en- nitus or balance disturbances, without any harm- larged in recent years, thanks to a better knowl- ful consequence, has widened in the last few edge and a more specific attention of pharma- years. The reason for this is the progress of scien- ceutical firms and drug-control institutions. In tific knowledge, the increased awareness of the daily clinical practice, there is a need for the pharmaceutical companies and of the institutions, family physician and the ENT specialist or audi- ologist (also in consideration of the possible which supervise pharmaceutical production. medico-legal implications) to focus the attention Only through continuous updating and experi- on the possible risk of otological side effects. ence sharing it’s possible to offer patients the This would allow a clinical risk-benefit evalua- certainty of receiving the treatment that is appro- tion, weighing the possible clinical advantage in priate, safe and effective and based upon the their field of competence against possible oto- most credited clinical studies.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0176792 A1 Gant Et Al
    US 20090176792A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0176792 A1 Gant et al. (43) Pub. Date: Jul. 9, 2009 (54) SUBSTITUTED Publication Classification DBENZHYDRYLPPERAZINES (51) Int. Cl. A63/4985 (2006.01) (75) Inventors: Thomas G. Gant, Carlsbad, CA C07D 24I/04 (2006.01) (US); Sepehr Sarshar, Cardiff by A63/495 (2006.01) the Sea, CA (US) (52) U.S. Cl. ..................... 514/251544/396; 514/255.04 (57) ABSTRACT Correspondence Address: The present invention relates to new dibenzhydrylpiperazine GLOBAL PATENT GROUP - APX modulators of histamine receptors, pharmaceutical composi Ms. LaVern Hall tions thereof, and methods of use thereof. 10411 Clayton Road, Suite 304 ST. LOUIS, MO 63131 (US) Formula I (73) Assignee: AUSPEX PHARMACEUTICALS, INC., Vista, CA (US) (21) Appl. No.: 12/350,032 (22) Filed: Jan. 7, 2009 Related U.S. Application Data (60) Provisional application No. 61/019.520, filed on Jan. 7, 2008. US 2009/0176792 A1 Jul. 9, 2009 SUBSTITUTED 0005 Disclosed herein is a compound having structural DBENZHYDRYLPPERAZINES Formula I: (I) 0001. This application claims the benefit of priority of U.S. provisional application No. 61/019,520, filed Jan. 7, 2008, the disclosure of which is hereby incorporated by ref erence as if written herein in its entirety. 0002 The present invention is directed to dibenzhy drylpiperazine-based histamine receptor modulators and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of Such com pounds for the treatment and/or management of nausea, kine tosis, emesis, Vertigo, dermatitis, migraines, labyrinthitis, Méniere's disease and/or any disorder ameliorated by modu lation of histamine receptors.
    [Show full text]
  • FDA-Approved Drug Library Mini (96-Well)
    • Inhibitors • Agonists • Screening Libraries www.MedChemExpress.com FDA-Approved Drug Library Mini (96-well) Product Details: Catalog Number: HY-L022M Formulation: A collection of 1559 marketed drugs supplied as pre-dissolved DMSO solutions Container: 96 Well Microplate With Peelable Foil Seal Storage: -80°C Shipping: Blue ice Packaging: Inert gas Plate layout: HY-L022M-1 1 2 3 4 5 6 7 8 9 10 11 12 Plerixafor Zoledronic a Empty Sisomicin Streptomycin (octahydrochl acid Paromomycin Netilmicin Neomycin Levoleucovori Peramivir Capreomycin Empty (sulfate) (sulfate) oride) (monohydrate (sulfate) (sulfate) (sulfate) n (Calcium) (trihydrate) (sulfate) 4- L-Glutamic b Empty Amikacin Stibogluconat Gluconate Histamine Mangafodipir Cromolyn (Aminomethyl acid Citicoline Tranexamic Empty (sulfate) e (sodium) (Calcium) (phosphate) (trisodium) (sodium) )benzoic acid monosodium acid Ozagrel Chloroquine Heparin Sugammadex Citicoline Ribostamycin c Empty sodium (diphosphate) Gadobutrol L-Ornithine (sodium salt) (sodium) Zanamivir sodium salt (sulfate) Glucosamine Empty d Empty L-Arginine Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty e Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty f Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty g Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty h Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Empty Plate layout: HY-L022M-2 1 2 3 4 5 6 7 8 9 10 11 12 Etomidate Epirubicin Tetramisole a Empty Ibrutinib (hydrochlorid
    [Show full text]